Vemurafenib-induced progression of breast cancer: a case report and review of the literature.
Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild-type malignancies remains insufficiently studied. We observed a patient, who was administered vemurafenib for BRAF mutation-containing melanoma, but experienced immediate relapse of previously controlled breast cancer disease. Interestingly, breast cancer lesions underwent regression soon after vemurafenib discontinuation. Therefore, caution must be taken while considering vemurafenib treatment for patients with multiple tumors.
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia. anovik@list.ru.|St. Petersburg Pediatric Medical University, St. Petersburg, 194100, Russia. anovik@list.ru.
Aleksei V
AV
Novik
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Svetlana A
SA
Protsenko
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.|I.I. Mechnikov North-Western Medical University, St. Petersburg, 191015, Russia.
Irina A
IA
Baldueva
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Aleksander O
AO
Ivantsov
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.|I.I. Mechnikov North-Western Medical University, St. Petersburg, 191015, Russia.
Tatyana L
TL
Nekhaeva
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.
Zinaida Y
ZY
Akhaeva
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.|St. Petersburg Pediatric Medical University, St. Petersburg, 194100, Russia.
Grigoriy A
GA
Yanus
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.|St. Petersburg Pediatric Medical University, St. Petersburg, 194100, Russia.
Aglaya G
AG
Iyevleva
N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.|St. Petersburg Pediatric Medical University, St. Petersburg, 194100, Russia.|I.I. Mechnikov North-Western Medical University, St. Petersburg, 191015, Russia.|St. Petersburg State University, St. Petersburg, 199034, Russia.
Evgeny N
EN
Imyanitov
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced* / Q000473:pathology; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000378:metabolism; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D000077484:Vemurafenib
D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf